QC Laboratories, Inc. Awarded Nadcap Certification for Computed Radiography
19.7.2023 14:59:00 EEST | Business Wire | Press release
QC Laboratories, Inc., a leading nondestructive testing and inspection services company, has announced that it has been awarded Nadcap certification for computed radiography (AC7114/10S) by the Performance Review Institute (PRI).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230717661945/en/
(Photo: Business Wire)
The Nadcap certification is a highly respected accreditation that recognizes companies that demonstrate exceptional quality and performance in the aerospace industry. QC Laboratories, Inc. has met the rigorous requirements of the Nadcap audit for computed radiography, which includes stringent technical and quality standards, as well as an assessment of the company's personnel, facilities, and processes.
"We are thrilled to have achieved this certification, which reflects our unwavering commitment to providing the highest quality nondestructive testing and inspection services to our customers," said Jose Crespo, General Manager of QC Laboratories, Inc. "With the addition of Nadcap certification for Computed Radiography per ASTM E2033, combined with our powerful 450kV x-ray system, we are better equipped to serve our Nadcap subscriber customers in aerospace & defense, space, and beyond."
Computed radiography is a nondestructive testing method that uses digital imaging technology to produce high-quality images of internal structures and components. This technology enables the detection of defects and discontinuities in materials, such as cracks, porosity, and inclusions, without damaging them.
QC Laboratories, Inc. has had remarkable success in identifying defects in metal additive manufacturing parts using computed radiography. The company has been able to detect defects as small as 25 microns, which is crucial for ensuring the quality and reliability of complex metal parts made from exotic and refractory metals like those used in aircraft and rocket engine components, where high strength and thermodynamics are required.
With the new Nadcap certification for computed radiography (AC7114/10S), QC Laboratories, Inc. is now able to offer computed radiography services that meet the rigorous quality and technical standards of the aerospace industry. This certification further strengthens the company's position as a trusted provider of nondestructive testing and inspection services to customers in a wide range of industries.
About QC Laboratories, Inc.
QC Laboratories, Inc. is a nondestructive testing laboratory in Hollywood, Florida, USA. The company was founded in 1965 and offers various testing services, including nondestructive testing (NDT), chemical processing, and consulting services.
QC Laboratories serves a variety of industries, including aerospace, additive manufacturing, automotive, defense, manufacturing, and consumer products. The laboratory is accredited by the American Society for Nondestructive Testing (ASNT) and is certified by the Federal Aviation Administration (FAA) and Nadcap (Performance Review Institute) for NDT services.
QC Laboratories has a team of experienced nondestructive engineers and technicians using advanced testing equipment and techniques to provide accurate and reliable results. The laboratory is committed to delivering high-quality services and maintaining the highest standards of professionalism and ethics.
For more information about QC Laboratories' new capability for pre-penetrant etching of metal AM parts, please visit www.qclabs.net or contact the laboratory directly.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230717661945/en/
Contact information
Althea Lawson
QC Laboratories, Inc.
Phone: (954) 925-0499
Email: info@qclabs.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 15:29:00 EEST | Press release
Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level
Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
